

4DMedical unveils world's first dedicated lung scanner

17 March 2022

Highlights

- 4DMedical has successfully developed the world's first and only dedicated lung scanner, deploying an XV Scanner ahead of schedule at the Prince of Wales Hospital in Sydney
- 4DMedical will unveil the XV Scanner today at a ceremony involving Greg Hunt, Federal Minister for Health, industry partners and the University of New South Wales
- The XV Scanner integrates 4DMedical's proprietary XV Technology™ software into a dedicated lung scanner
- This new product offers multiple pathways to drive the Company's commercialisation plans

Melbourne, Australia, 17 March 2022: Global medical technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the launch of the XV Scanner, the world's first dedicated lung scanner.

The XV Scanner integrates 4DMedical's XV Technology™ into a purpose-built platform providing doctors and patients with unprecedented and highly visual insight into lung function.

The scanner was delivered with the help of the Medical Research Future Fund (MRFF), through which the Australian government is contributing A\$28.9m, towards the outcome of dramatically increasing patient access to the benefits of XV TechnologyTM.

4DMedical software + XV Scanner = accelerated uptake

The Company has successfully combined its proprietary XV Technology™ with purpose-built hardware to create the XV Scanner. The device provides detailed quantitative data on respiratory function via an automated scanning process. Importantly, this product offers multiple pathways to drive the Company's commercialisation plans. Specifically, the scanner:


- Increases throughput, reducing costs for healthcare providers;
- Facilitates access to XV Technology™ for more patients, including children and the very unwell unable to be scanned using conventional imaging equipment; thereby
- Accelerating uptake of the Company's core SaaS product.

The future of lung health

Melbourne 7/700 Swanston Street, Carlton, Victoria, 3053 Tel: +61 (3) 9545 5940

Los Angeles 21600 Oxnard Street #300, ABN: 31 161 684 831 Tel: +1 (818) 794-6467

4DMedical Limited Woodland Hills, 91367, CA Email: info@4DMedical.com 4DMedical.com



Digital rendering of 4D Medical's XV Scanner installed at Prince of Wales Hospital

Scanner delivered ahead of schedule

4DMedical has met its target to deploy the first XV Scanner in an Australian hospital within 12 months of the commencement of Stage2 funding. This ambitious target has been realised with today's unveiling of the first device at the Prince of Wales Hospital in Sydney in the presence of Federal Minister for Health, Greg Hunt and industry partners.

Engineering research and development was completed in-house in Australia, achieving sovereign capability whilst creating of a significant body of intellectual property that has already generated three patents.

4DMedical Founder, Managing Director and Chief Executive Officer Dr Andreas Fouras, said: "The unveiling of 4DMedical's new purpose-built scanner is great news on multiple fronts. From a project delivery angle, the XV Scanner was completed on time and within budget despite challenges created by the ongoing COVID-19 pandemic. From the viewpoint of doctors and patients, the scanner represents a seminal event in the global evolution of respiratory diagnostics, and from a commercialisation perspective, this scanner creates multiple opportunities to drive adoption of XV Technology™.



We are extremely proud that the scanner was designed and manufactured in Australia. Its development is another demonstration of 4DMedical's ability to deliver cutting edge technology that can be sold within Australia and exported around the globe."

Lung Foundation Australia Chief Executive Mark Brooke said: "Today's announcement by 4DMedical signals a breakthrough in innovation, holding significant promise for the seven million Australians living with or impacted by lung disease.

This new technology promises to revolutionise diagnostic and imaging procedures for a range of lung diseases impacting children, adults and older Australians. Lung Foundation Australia is proud to partner with 4DMedical to bring this Australian innovation and technology to patients."

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate:	Media:
Melanie Leydin	Julia Maguire
Company Secretary	+61 2 8999 3699
<pre>companysecretary@4dmedical.com</pre>	julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly the understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[™], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[™]), which is the first and only modality that can dynamically quantify ventilation in four dimensions.

Additionally, XV Technology[™] exposes the patient to lower levels of radiation relative to other diagnostic methods and without the need for contrast agents – a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

4DMedical's XV LVAS[™] Ventilation Reports are prepared utilising a Software as a Service workflow and delivery model using existing hospital imaging equipment or the company's own revolutionary XV Scanner.

To learn more, visit: www.4dmedical.com/